These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 34815553)

  • 1. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.
    Tamaki N; Ajmera V; Loomba R
    Nat Rev Endocrinol; 2022 Jan; 18(1):55-66. PubMed ID: 34815553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
    Wildman-Tobriner B; Middleton MM; Moylan CA; Rossi S; Flores O; Chang ZA; Abdelmalek MF; Sirlin CB; Bashir MR
    Gastroenterology; 2018 Nov; 155(5):1428-1435.e2. PubMed ID: 30031769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic Resonance Imaging Proton Density Fat Fraction Associates With Progression of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Ajmera V; Park CC; Caussy C; Singh S; Hernandez C; Bettencourt R; Hooker J; Sy E; Behling C; Xu R; Middleton MS; Valasek MA; Faulkner C; Rizo E; Richards L; Sirlin CB; Loomba R
    Gastroenterology; 2018 Aug; 155(2):307-310.e2. PubMed ID: 29660324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates.
    Garteiser P; Castera L; Coupaye M; Doblas S; Calabrese D; Dioguardi Burgio M; Ledoux S; Bedossa P; Esposito-Farèse M; Msika S; Van Beers BE; Jouët P
    JHEP Rep; 2021 Dec; 3(6):100381. PubMed ID: 34786549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
    Tamaki N; Munaganuru N; Jung J; Yonan AQ; Loomba RR; Bettencourt R; Ajmera V; Valasek MA; Behling C; Sirlin CB; Loomba R
    Gut; 2022 May; 71(5):983-990. PubMed ID: 33883248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of liver fat content as determined by magnetic resonance imaging-proton density fat fraction and MRS versus liver histology in non-alcoholic fatty liver disease.
    Idilman IS; Keskin O; Celik A; Savas B; Elhan AH; Idilman R; Karcaaltincaba M
    Acta Radiol; 2016 Mar; 57(3):271-8. PubMed ID: 25855666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of Magnetic Resonance Imaging Biomarkers for Identifying Nonalcoholic Steatohepatitis Patients at High Risk of Progression: A Multicenter Pooled Data and Meta-Analysis.
    Andersson A; Kelly M; Imajo K; Nakajima A; Fallowfield JA; Hirschfield G; Pavlides M; Sanyal AJ; Noureddin M; Banerjee R; Dennis A; Harrison S
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2451-2461.e3. PubMed ID: 34626833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD.
    Permutt Z; Le TA; Peterson MR; Seki E; Brenner DA; Sirlin C; Loomba R
    Aliment Pharmacol Ther; 2012 Jul; 36(1):22-9. PubMed ID: 22554256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver fat quantification: where do we stand?
    Starekova J; Reeder SB
    Abdom Radiol (NY); 2020 Nov; 45(11):3386-3399. PubMed ID: 33025153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique.
    Lin SC; Heba E; Wolfson T; Ang B; Gamst A; Han A; Erdman JW; O'Brien WD; Andre MP; Sirlin CB; Loomba R
    Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1337-1345.e6. PubMed ID: 25478922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI-PDFF in NAFLD.
    Kim BK; Bernstein N; Huang DQ; Tamaki N; Imajo K; Yoneda M; Sutter N; Jung J; Nguyen K; Nguyen L; Le T; Madamba E; Richards L; Valasek MA; Behling C; Sirlin CB; Nakajima A; Loomba R
    Aliment Pharmacol Ther; 2023 Jul; 58(2):229-237. PubMed ID: 37269117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials.
    Caussy C; Reeder SB; Sirlin CB; Loomba R
    Hepatology; 2018 Aug; 68(2):763-772. PubMed ID: 29356032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes.
    Denimal D; Béland-Bonenfant S; Pais-de-Barros JP; Rouland A; Bouillet B; Duvillard L; Vergès B; Petit JM
    Cardiovasc Diabetol; 2023 Nov; 22(1):310. PubMed ID: 37940926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease.
    Lee SJ; Kim SU
    Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):523-530. PubMed ID: 31018719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiologic evaluation of nonalcoholic fatty liver disease.
    Lee SS; Park SH
    World J Gastroenterol; 2014 Jun; 20(23):7392-402. PubMed ID: 24966609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Ultrasound Radiofrequency Data Analysis for the Assessment of Hepatic Steatosis in Nonalcoholic Fatty Liver Disease Using Magnetic Resonance Imaging Proton Density Fat Fraction as the Reference Standard.
    Jeon SK; Lee JM; Joo I; Park SJ
    Korean J Radiol; 2021 Jul; 22(7):1077-1086. PubMed ID: 33739636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging biomarkers of NAFLD, NASH, and fibrosis.
    Ajmera V; Loomba R
    Mol Metab; 2021 Aug; 50():101167. PubMed ID: 33460786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis.
    Noureddin M; Truong E; Gornbein JA; Saouaf R; Guindi M; Todo T; Noureddin N; Yang JD; Harrison SA; Alkhouri N
    J Hepatol; 2022 Apr; 76(4):781-787. PubMed ID: 34798176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
    Middleton MS; Heba ER; Hooker CA; Bashir MR; Fowler KJ; Sandrasegaran K; Brunt EM; Kleiner DE; Doo E; Van Natta ML; Lavine JE; Neuschwander-Tetri BA; Sanyal A; Loomba R; Sirlin CB;
    Gastroenterology; 2017 Sep; 153(3):753-761. PubMed ID: 28624576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
    Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
    J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.